Antacids Market By Mechanism of Action, By Formulation Type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The antacids market valued for $6,678.82 million in 2022 and is estimated to reach $9,068.47 million by 2032, exhibiting a CAGR of 3.1% from 2023 to 2032.

Antacid is a medication that is used to alleviate heartburn and indigestion. These medications act by reducing the amount of hydrochloric acid secreted in the stomach. The stomach secretes hydrochloric acid to carry out the digestion process. As the acid is corrosive, a mucous barrier protects the lining of the stomach from being eroded. However, acid reflux or issues associated with the mucous barrier can result in heartburn. This In such cases, antacids are used to neutralize the acid present in the stomach to produce a neutral substance, such as water or salt. This reduces the acidity in the stomach and relieves symptoms of heartburn and indigestion.

Antacids are available in various types of formulations such as tablets, liquids, and others, along with a range of flavors and strengths. These medications are safe to use in moderation and can be effective for mild symptoms. Common ingredients in antacids include aluminum hydroxide, magnesium hydroxide, calcium carbonate, and sodium bicarbonate. Some antacids are given in combination such as simethicone along with calcium carbonate or magnesium hydroxide and simethicone, which is used to relieve gas and bloating.

The growth of the global antacids market is driven increase in prevalence of acid-related conditions, convenience & accessibility of over-the-counter (OTC) antacids, and rise in number of patients engaging in self-medication. Acid-related conditions involve a range of gastrointestinal disorders that are caused by excessive secretion of gastric acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, and dyspepsia. Increase in prevalence of these acid-related conditions acts as a major driver of the antacids market. For instance, according to the National Library of Medicine in 2020, more than 60 million Americans experience heartburn at least once a month.

However, excessive use of antacids leads to a range of side effects that potentially hinder the growth of the market. For instance, antacids may affect the levels of electrolytes in the body, such as sodium, potassium, and calcium. In addition, prolonged use of antacids can put strain on the kidneys, leading to problems such as kidney stones or renal failure. In addition, low awareness about acid reflux, gastroesophageal reflux disease (GERD), and other conditions and available treatment among the population of underdeveloped countries acts as a key restraint of the market.

On the contrary, increase in focus of manufacturers to develop cost-effective and wide range of medications with less side effects is expected to offer lucrative opportunities for the market growth. For instance, Alkem Laboratories offers Omee MPS liquid, which is available in a range of flavors such as mint, orange, and saunf as well as Omee Chewtabs, which are available in the same flavors. These antacids are affordable, and thus, have witnessed increased adoption in developing and developed countries.

In addition, people in underdeveloped countries are becoming aware about antacid medications available in the market and their use in managing acidity and other acid-related conditions. This is anticipated to boost the market during the forecast period. In addition, emerging countries in Asia-Pacific and LAMEA are characterized by presence of large population base along with rapid economic growth and increase in healthcare expenditure. All these factors are anticipated to increase the demand for antacids in these regions, thereby boosting the global market growth.

The global antacids market is segmented into medication type, formulation type, distribution channel, and region. By product, the market is bifurcated into systemic antacids and non-systemic antacids. On the basis of formulation type, it is categorized into tablet, liquids, and others. By distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the Abbott Laboratories, Pfizer Inc., Prestige Consumer Healthcare Inc., Cipla Ltd, Reckitt Benckiser Group PLC, Haleon plc, Bayer AG, Alkem Laboratories Ltd., WellSpring Pharmaceutical Corporation and Infirst Healthcare Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antacids market analysis from 2022 to 2032 to identify the prevailing antacids market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antacids market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antacids market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Mechanism of Action

Systemic Antacids
Non-systemic Antacids

By Formulation Type

Tablets
Liquids
Others

By Distribution channel

Hospital pharmacies
Drug stores and retail pharmacies
Online providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Abbott Laboratories
Alkem Laboratories Ltd.
Bayer AG
Cipla Ltd
Haleon plc
Infirst Healthcare Inc.
Pfizer Inc.
Prestige Consumer Healthcare Inc.
Reckitt Benckiser Group PLC
WellSpring Pharmaceutical Corporation

Product Code: A10281

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of acid reflux and GERD
  - 3.4.1.2. Easy availability of OTC antacids
  - 3.4.1.3. Surge in demand for antacids among geriatric population

3.4.2. Restraints
- 3.4.2.1. Limitations related to use of antacids
- 3.4.2.2. Emergence of alternative treatments

3.4.3. Opportunities
- 3.4.3.1. Rapidly changing lifestyle of global population

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTACIDS MARKET, BY MECHANISM OF ACTION

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Systemic Antacids
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Non-systemic Antacids
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: ANTACIDS MARKET, BY FORMULATION TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Tablets
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Liquids
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: ANTACIDS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: ANTACIDS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Mechanism of Action
- 7.2.3. Market size and forecast, by Formulation Type
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.2.5.1.3. Market size and forecast, by Formulation Type
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.2.5.2.3. Market size and forecast, by Formulation Type
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.2.5.3.3. Market size and forecast, by Formulation Type
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Mechanism of Action
- 7.3.3. Market size and forecast, by Formulation Type
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.1.3. Market size and forecast, by Formulation Type
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.2.3. Market size and forecast, by Formulation Type
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.3.3. Market size and forecast, by Formulation Type
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.4.3. Market size and forecast, by Formulation Type
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.5.3. Market size and forecast, by Formulation Type
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.6.3. Market size and forecast, by Formulation Type
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Mechanism of Action
- 7.4.3. Market size and forecast, by Formulation Type
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.1.3. Market size and forecast, by Formulation Type
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.2.3. Market size and forecast, by Formulation Type
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.3.3. Market size and forecast, by Formulation Type
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.4.3. Market size and forecast, by Formulation Type
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.5.3. Market size and forecast, by Formulation Type
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.6.3. Market size and forecast, by Formulation Type
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Mechanism of Action
- 7.5.3. Market size and forecast, by Formulation Type
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.1.3. Market size and forecast, by Formulation Type
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.2.3. Market size and forecast, by Formulation Type
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.3.3. Market size and forecast, by Formulation Type
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.4.3. Market size and forecast, by Formulation Type
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Bayer AG
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Alkem Laboratories Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Cipla Ltd
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Pfizer Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. WellSpring Pharmaceutical Corporation
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Haleon plc
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Prestige Consumer Healthcare Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Reckitt Benckiser Group PLC
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Infirst Healthcare Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
9.10. Abbott Laboratories
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance